Pathogenesis and treatment of HTLV-I associated myelopathy

Sexually Transmitted Infections

Volumn 74, Issue 5, 1998, Pages 316-322

  Taylor, Graham P ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ASCORBIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DANAZOL; ERYTHROMYCIN; FOSFOMYCIN; HEPARIN; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LAMIVUDINE; METHYLPREDNISOLONE; MIZORIBINE; PENTOXIFYLLINE; PROTIRELIN; SALAZOSULFAPYRIDINE; TAX PROTEIN; ZIDOVUDINE;

BLADDER DYSFUNCTION; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HUMAN TISSUE; IMPOTENCE; INFLAMMATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVIRUS; REVIEW; SEROLOGY; SPINAL CORD DISEASE; TREPONEMA PALLIDUM; VIRUS GENE;

EID: 0031687601     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.74.5.316     Document Type: Review

References (50)

1. Strachan H. On a form of multiple neuritis prevalent in the West Indies. Practitioner 1888;59:477.
2. Cruikshank EK. A neuropathic syndrome of uncertain origin. West Indian Med J 1956;5:147.
3. Gessain A, Vernant JC, Maurs L, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;ii:407-9.
4. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukaemia: clinical and haematological features of 16 cases. Blood 1977;50:481-92.
5. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukaemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci (USA) 1981;78:6476-80.
6. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity (letter). Lancet 1986;i: 1031-2.
7. Daenke S, Parker CE, Niewiesk S, et al. Spastic paraparesis in a patient carrying defective HTLV-I proviral sequences but lacking a humoral or cytotoxic T-cell response to HTLV-I. J Inject Dis 1994;169:941.
8. IARC monographs on the evaluation of carcinogenic risk to humans. Vol 67 human immunodeficiency viruses and human T-cell lymphotrophic viruses. Lyons: International Agency for Research on Cancer, 1996.
9. Kinoshita T, Tsujimoto A, Shimotohno K. Sequence variations in LTR and env regions of HTLV-I do not discriminate between the virus from patients with HTLV-I-associated myelopathy and adult T-cell leukemia. Int J Cancer 1991;47:491-5.
10. Hildreth JEK, Roos J, Liao Z. VCAM-I mediates HTLV-I infection through the integrin α4β7 and requires a cellular phosphate. [Abstract 577] Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, 1-5 Feb 1998:188.
11. Wattel E, Cavrois M, Gessain A, et al. Clonal expansion of infected cells. A way of life for HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 (Suppl 1):S92-9.
12. The HTLV European Research Network. Seroepidemiology of human T-cell leukaemialymphoma viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:68-77.
13. Rodgers-Johnson PEB. Tropical myeloneuropathies in Jamaica (Jamaican neuropathy) in HTLV-1 and the nervous system. New York: Alan R Liss, 1989:123-38.
14. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096-101.
15. Jeannel D, Garin B, Kazadi K, et al. The risk of tropical spastic paraparesis differs according to ethnic group among HTLV-I carriers in Inongo, Zaire. J Acquir Immune Defic Syndr 1993;6:840-4.
16. Maloney EM, Cleghorn F, Morgan OSC, et al. HAM/TSP incidence rate is higher among females compared to males in Jamaica and Trinidad. [Abstract ED39] Proceedings of the VIIIth International Conference on Human Retrovirology: HTLV. Rio de Janeiro, 9-13 June 1997.
17. Murphy EL, Fridey J, Smith JW, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology 1997;48: 315-20.
18. Akizuki S, Nakazato O, Higuchi Y, et al. Necropsy findings in HTLV-I associated myelopathy. Lancet 1987;i:56-7.
19. Montgomery RD, Cruickshank EK, Robertson WB, et al. Clinical and pathological observation on Jamaican neuropathy Brain 1964;87:425-52.
20. Cartier LM, Cea G, Vegara C, et al. Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. J Neuropath Exp Neurol 1997;56:403-13.
21. Iwasaki Y, Ohara Y, Kobayashi I, et al. Infiltration of helper/ inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 1992;140:1003-8.
22. Osame M, Ijichi S, Arimura K, et al. HTLV-I-associated myelopathy. In: Höllsberg P, Hafler DA, eds. Human T-cell lymphotropic virus type I. Chichester: John Wiley, 1996:197-218.
23. Lehky TJ, Fox CH, Keonig S, et al. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/ tropical spastic paraparesis patients by in situ hybridization. Ann Neurol 1995;37:167-75.
24. Kubota R, Fujiyoshi T, Izumo S, et al. Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy. J Neuroimmunol 1993;42:147-54.
25. Taylor GP, Tosswill JHC, Matutes E, et al. A longitudinal prospective study of HTLV-I infection. Vol 1. XIIth International Conference on AIDS, Vancouver, 7-12 July 1996: 219 [Abstract Tu.A. 161].
26. Jacobson S, Shida H, McFarlin DE, et al. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990;348:245-8.
27. Parker CE, Nightingale S, Taylor GP, et al. Circulating antitax cytotoxic T lymphocytes from human T-cell leukaemia virus type I-infected people, with and without Tropical Spastic Paraparesis, recognise multiple epitopes simultaneously. J Virol 1994;68:2860-8.
28. Biddeson WE, Kubota R, Kawanishi T, et al. Human T-cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines and matrix metalloproteinase. J Immunol 1997;159:2018-25.
29. Moritoyo T, Reinhart T, Moritoyo H, et al. Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. Ann Neurol 1996;40:84-90.
30. Höllsberg P. Pathogenesis of chronic progressive myelopathy associated with human T-cell lyemphotropic virus type I. Acta Neurol Scand 1997; (suppl) 169:86-93.
31. Matsuo H, Tsujihata M, Satoh A, et al. Plasmapheresis in treatment of human T-lymphotropic virus type -I associated myelopathy. Lancet 1988;ii:1109-13.
32. Matsuo H, Nakamura T, Shibayama K, et al. Long-term follow-up of immunomodulation in treatment of HTLV-I associated myelopathy (letter). Lancet 1990;i:790.
33. Osame M, Igata A, Matsumoto M, et al. HTLV-I associated myelopathy (HAM): treatment trials, retrospective survey and clinical laboratory findings. Hematol Rev 1990;3:271-84.
34. Nakamura T, Shibayama, Nagasato K, et al. The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy. Jpn J Med 1990;29:362-7.
35. Kuroda Y, Takashima H, Ikeda A, et al. Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol 1991;238:309-14.
36. Kira J, Fujihara K, Itoyama Y, et al. Leukoencephalopathy in HTLV-I associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 1991;106:41-9.
37. Harrington WJ Jr, Sheremata WA, Snodgrass S, et al. Tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res. Human Retroviruses 1991;7:1031-4.
38. Shibayama K, Nakamura T, Nagasato K, et al. Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects. J Neurol Sci 1991;106:186-92.
39. Gout O, Gessain A, Iba-Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-I (letter). J Neurol 1991;238:108-9.
40. Kuroda Y, Kurohara K, Fujiyama F, et al. Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand 1992;86:82-6.
41. Nagasato K, Nakamura T, Ichinose K, et al. Heparin treatment in patients with human T lymphotropic virus type-I-associated myelopathy: a preliminary study. J Neurol Sci 1993;115:161-8.
42. Sheremata WA, Benedict BS, Squilacote DC, et al. High-dose zidovudine induction in HTLV-I associated myelopathy: safety and possible efficacy. Neurology 1993; 43:2125-9.
43. Misra AK, Mishra SK, Eigen AC, et al. Successful immunosuppressive therapy for HTLV-I associated myelopathy. J Neurol Sci 1994;122:155-6.
44. Kataoka A, Imai H, Inayoshi S, et al. Intermittent high dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 1993;56:1213-16.
45. Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996;46: 1016-21.
46. Shirabe S, Nakamura T, Tsujino A, et al. Successful application of pentoxifylline in the treatment of HTLV-I-associated myelopathy. J Neurol Sci 1997;151:97-101.
47. Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-I associated myelopathy/ tropical spastic paraparesis. J Neurovirol 1996;2:345-55.
48. Yamasaki K, Kira J, Koyanagi Y, et al. Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 1997;147:135-44.
49. Ichinose K, Nakamura T, Kawakami A, et al. Increased adherence of T-cells to human endothelial cells in patients with human T-cell lymphotropic virus type-I-associated myelopathy. Arch Neurol 1992;49:74-6.
50. Taylor GP, Hall S, Nowak M, et al. Reduction of HTLV-I proviral load in patients with HTLV-I associated myelopathy through lamivudine monotherapy. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1-5 February 1998:175 [Abstract 508].